Autoimmune liver diseases and inflammatory bowel diseases in children: current issues and future perspectives

References

• IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis – the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1–7.
   PubMed Web of Science ®Google Scholar
• Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? WJG. 2011;17:2702–2707.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Puttini PS, Cassinotti A, et al. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40(Suppl 2):S253–S259.
   Google Scholar
• Guariso G, Gasparetto M, Visonà Dalla Pozza L, et al. Inflammatory bowel disease developing in paediatric and adult age. J Pediatr Gastroenterol Nutr. 2010;51:698–707.
   PubMed Web of Science ®Google Scholar
• Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010;51:140–145.
   PubMed Web of Science ®Google Scholar
• Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:63–68.
   PubMed Web of Science ®Google Scholar
• Zippi M, Corrado C, Pica R, et al. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol. 2014;20:17463–17467.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–119.
   PubMed Web of Science ®Google Scholar
• Isene R, Bernklev T, Høie O, et al., on behalf of the EC-IBD Study Group. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–305.
   PubMed Web of Science ®Google Scholar
• Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 2002; 31:307–327.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598–1619.
   PubMed Web of Science ®Google Scholar
• Goyal A, Hyams JS, Lerer T, et al., Pediatric Inflammatory Bowel Disease Collaborative Research Group. Liver enzyme elevations within 3 months of diagnosis of inflammatory bowel disease and likelihood of liver disease. J Pediatr Gastroenterol Nutr. 2014;59:321–323.
   PubMed Web of Science ®Google Scholar
• Rojas-Feria M, Castro M, Suárez E, et al. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. WJG. 2013;19:7327–7340.
   PubMed Web of Science ®Google Scholar
• Gizard E, Ford AC, Bronowicki JP, et al. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:3–15.
   PubMed Web of Science ®Google Scholar
• Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:157–165.
   PubMed Web of Science ®Google Scholar
• de Ridder L, Turner D, Wilson DC, et al., Porto IBD Working Group of ESPGHAN. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the Porto Pediatric IBD Group. Inflamm Bowel Dis. 2014;20:291–300.
   PubMed Web of Science ®Google Scholar
• Martinelli M, Strisciuglio C, Illiceto MT, et al., IMIBD Group of the Italian Society for Paediatric Gastroenterology, Hepatology and Nutrition. Natural history of pancreatic involvement in paediatric inflammatory bowel disease. Dig Liver Dis. 2015;47:384–389.
   PubMedGoogle Scholar
• Heikius B, Niemelä S, Lehtola J, et al. Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand J Gastroenterol. 1997;32:153–161.
   PubMed Web of Science ®Google Scholar
• Portmann B, Zen Y. Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology. 2012;60:236–248.
   PubMed Web of Science ®Google Scholar
• Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33:544–553.
   PubMed Web of Science ®Google Scholar
• Beuers U, Rust C. Overlap syndromes. Semin Liver Dis. 2005;25:311–320.
   PubMed Web of Science ®Google Scholar
• Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. WJG. 2008;14:331–337.
   PubMed Web of Science ®Google Scholar
• Pollheimer MJ, Halilbasic E, Fickert P, et al. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25:727–739.
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–1049.
   PubMed Web of Science ®Google Scholar
• Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 2002;51:562–566.
   PubMed Web of Science ®Google Scholar
• Ellinghaus D, Folseraas T, Holm K, et al. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology. 2013;58:1074–1083.
   PubMed Web of Science ®Google Scholar
• Karlsen TH, Boberg KM, Vatn M, et al., IBSEN Study Group. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun. 2007;8:275–278.
   PubMed Web of Science ®Google Scholar
• Navaneethan U. Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf). 2014;2:193–200.
   PubMedGoogle Scholar
• Terjung B, Spengler U, Sauerbruch T, et al. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 2000;119:310–322.
   PubMed Web of Science ®Google Scholar
• Stinton LM, Bentow C, Mahler M, et al. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). PLoS One. 2014;9:e112877.
   PubMed Web of Science ®Google Scholar
• Liaskou E, Karikoski M, Reynolds GM, et al. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology. 2011;53:661–672.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015;37:47–55.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, O'Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol. 2014;49:901–908.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int. 2013;2013:389537.
   PubMed Web of Science ®Google Scholar
• Ma HD, Wang YH, Chang C, et al. The intestinal microbiota and microenvironment in liver. Autoimmun Rev. 2015;14:183–191.
   PubMed Web of Science ®Google Scholar
• Venkatesh PG, Navaneethan U, Shen B. Hepatobiliary disorders and complications of inflammatory bowel disease. J Dig Dis. 2011;12:245–256.
   PubMed Web of Science ®Google Scholar
• Lundqvist K, Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis. A case control study. Dis Colon Rectum. 1997;40:451–456.
   PubMed Web of Science ®Google Scholar
• Malaty HM, Abraham BP, Mehta S, et al. The natural history of ulcerative colitis in a pediatric population: a follow-up population-based cohort study. Clin Exp Gastroenterol. 2013;6:77–83.
   PubMedGoogle Scholar
• Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–96.
   PubMed Web of Science ®Google Scholar
• Boonstra K, van Erpecum KJ, van Nieuwkerk KM, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2270–2276.
   PubMed Web of Science ®Google Scholar
• Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26:31–41.
   PubMed Web of Science ®Google Scholar
• Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case–control study. Am J Surg Pathol. 2009;33:854–862.
   PubMed Web of Science ®Google Scholar
• Marelli L, Xirouchakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut. 2011;60:1224–1228.
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Venkatesh PG, Mukewar S, et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:540–546.
   PubMed Web of Science ®Google Scholar
• Treeprasertsuk S, Björnsson E, Sinakos E, et al. Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy. World J Gastrointest Pharmacol Ther. 2013;4:61–68.
   PubMedGoogle Scholar
• Yanai H, Matalon S, Rosenblatt A, et al. Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel disease. J Crohns Colitis. 2015;9:177–184.
   PubMed Web of Science ®Google Scholar
• Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet. 2002;360:1943.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14:138e43.
   Web of Science ®Google Scholar
• de Vries AB, Janse M, Blokzijl H, et al. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. WJG. 2015;21:1956–1971.
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV, Sandborn WJ, et al. Pediatric “PSC-IBD”: a descriptive report of associated inflammatory bowel disease among pediatric patients with psc. J Pediatr Gastroenterol Nutr. 2001;33:296–300.
   PubMed Web of Science ®Google Scholar
• Ibrahim SH, Lindor KD. Current management of primary sclerosing cholangitis in pediatric patients. Paediatr Drugs. 2011;13:87–95.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet. 2013;382:1587–1599.
   PubMed Web of Science ®Google Scholar
• Pallavicino F, Pellicano R, Reggiani S, et al. Inflammatory bowel diseases and primary sclerosing cholangitis: hepatic and pancreatic side effects due to azathioprine. Eur Rev Med Pharmacol Sci. 2013;17:84–87.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Bokemeyer B, et al., European Crohn’s and Colitis Organisation. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1–33.
   PubMed Web of Science ®Google Scholar
• Davies YK, Cox KM, Abdullah BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008;47:61–67.
   PubMed Web of Science ®Google Scholar
• Franceschet I, Cazzagon N, Del Ross T, et al. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. Eur J Gastroenterol Hepatol. 2016;28:508–513.
   PubMed Web of Science ®Google Scholar
• Bjoro K, Brandsaeter B, Foss A, et al. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis. 2006;26:69–79.
   PubMed Web of Science ®Google Scholar
• Ali AH, Carey EJ, Lindor KD. Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015;4:1–6.
   PubMed Web of Science ®Google Scholar
• Mosli MH, MacDonald JK, Bickston SJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:1151–1159.
   PubMed Web of Science ®Google Scholar
• Bressler B, Marshall JK, Bernstein CN, et al., Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the toronto consensus. Gastroenterology. 2015;148:1035–1058.e3.
   PubMed Web of Science ®Google Scholar
• Tanida S, Ozeki K, Mizoshita T, et al. Managing refractory Crohn’s disease: challenges and solutions. Clin Exp Gastroenterol. 2015;8:131–140.
   PubMedGoogle Scholar
• Wyant T, Estevam J, Yang L, et al. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry. 2016;90:168–176.
   PubMedGoogle Scholar